Order:
  1.  15
    Healing Without Waging War: Beyond Military Metaphors in Medicine and HIV Cure Research.Jing-Bao Nie, Adam Gilbertson, Malcolm de Roubaix, Ciara Staunton, Anton van Niekerk, Joseph D. Tucker & Stuart Rennie - 2016 - American Journal of Bioethics 16 (10):3-11.
    Military metaphors are pervasive in biomedicine, including HIV research. Rooted in the mind set that regards pathogens as enemies to be defeated, terms such as “shock and kill” have become widely accepted idioms within HIV cure research. Such language and symbolism must be critically examined as they may be especially problematic when used to express scientific ideas within emerging health-related fields. In this article, philosophical analysis and an interdisciplinary literature review utilizing key texts from sociology, anthropology, history, and Chinese and (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   10 citations  
  2.  25
    No More Militaristic and Violent Language in Medicine: Response to Open Peer Commentaries on “Healing Without Waging War: Beyond Military Metaphors in Medicine and HIV Cure Research”.Jing-Bao Nie, Stuart Rennie, Adam Gilbertson & Joseph D. Tucker - 2016 - American Journal of Bioethics 16 (12):9-11.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  3.  19
    Ethics of Treatment Interruption Trials in HIV Cure Research: Addressing the Conundrum of Risk/Benefit Assessment.Gail E. Henderson, Holly L. Peay, Eugene Kroon, Rosemary Jean Cadigan, Karen Meagher, Thidarat Jupimai, Adam Gilbertson, Jill Fisher, Nuchanart Q. Ormsby, Nitiya Chomchey, Nittaya Phanuphak, Jintanat Ananworanich & Stuart Rennie - forthcoming - Journal of Medical Ethics:medethics-2017-104433.
    Though antiretroviral therapy is the standard of care for people living with HIV, its treatment limitations, burdens, stigma and costs lead to continued interest in HIV cure research. Early-phase cure trials, particularly those that include analytic treatment interruption, involve uncertain and potentially high risk, with minimal chance of clinical benefit. Some question whether such trials should be offered, given the risk/benefit imbalance, and whether those who choose to participate are acting rationally. We address these questions through a longitudinal decision-making study (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark